November 18, 2026

  UPFRONT BRIEFING

Isomorphic Labs just raised $5B without naming a single molecule, a record private biotech round and the clearest sign yet that crossover money will still write cheques this size for an AI platform. Sellas, meanwhile, did it the old-fashioned way: a Phase 3 survival win in AML, followed within hours by a $150M offering.

In Washington, the White House pulled Heidi Overton’s FDA nomination on Tuesday evening, hours before today’s HELP committee vote, so the agency stays without a confirmed commissioner into another round of hearings. Jefferies London wraps Thursday, and Capricor’s deramiocel PDUFA lands Sunday.

TAPE ACTION

  • Biotech fell less than the market: XBI (0.4%) and NBI (0.7%) vs the S&P 500 (1.0%), with BBC (1.7%) weaker. XLV’s (1.4%) drop tracked managed care, where UnitedHealth (5.4%), Molina (5.1%) and Humana (3.9%) sold off after CMS’s Monday-night proposal to expand Medicare Advantage audits.

  • The S&P 500 closed at 7,340.53, a five-month low, and the Dow fell (1.6%) as software sold off: Salesforce (9.5%), Intuit (7.2%), ServiceNow (6.5%), IGV (3.3%). St. Louis Fed’s Musalem said up to four more hikes may be needed by spring, and the NAHB index fell to 25, a 14-year low. The 10Y slipped 2bp to 5.10% and the VIX rose 11% to 25.46. After the bell, Nvidia beat (revenue $115.84B vs $109.1B, Q4 guide ~$130B) and rose ~3% after hours.

THE BIG 3

1️⃣ — Isomorphic Labs raises record $5B Series C

  • Isomorphic Labs, Alphabet’s AI drug-design spinout, raised a $5B Series C co-led by Greenoaks and Sequoia Capital, with Alphabet and new investors including Andreessen Horowitz. It is the largest private biotech round on record, more than double its own $2.1B Series B in May.

  • Why it matters: $5B with no disclosed molecule and no trial running: Isomorphic has now raised $7.1B in six months, and this round alone beats the $3B Altos Labs debut that held the record since 2022. The money takes internal oncology and immunology programs into the clinic alongside partnered work for Lilly, Novartis and J&J, so the nearer-term read is deal leverage rather than data: a platform this well funded can demand bigger economics from pharma or keep assets in-house. Greenoaks and Sequoia paid up while the tech tape was punishing AI spend. The risk is plain. No AI-designed drug has been approved, Isomorphic has not named a candidate, and the valuation rests on preclinical claims and Demis Hassabis’ record.

2️⃣ — White House withdraws Heidi Overton FDA nomination

  • The White House withdrew Heidi Overton’s nomination for FDA commissioner on Tuesday evening, hours before the Senate HELP committee’s scheduled Wednesday vote, after opposition from Senate Republicans and MAHA allies.

  • Why it matters: The withdrawal landed after Tuesday’s close, hours before a HELP vote where Republicans hold a one-seat majority and MAHA allies had lined up against her. The FDA has now gone roughly six months without a confirmed commissioner, with new CNPV vouchers stalled and CRL publication apparently paused (Big 3, 13 Nov). Reviews are still moving: Nelkarmi cleared ten days early on Tuesday, so the exposure is policy rather than PDUFA dates. Accelerated-approval posture, the voucher program and how hard reviewers lean on ex-US data after the ivonescimab letter all sit with acting leadership. A new nominee restarts hearings, which pushes a confirmed commissioner into 2027.

  • Source: STAT

3️⃣ — Sellas vaccine wins Phase 3 survival in AML, then raises $150M

  • Sellas’ galinpepimut-S (GPS), a WT1-targeted cancer vaccine, met the overall survival primary endpoint of the pivotal Phase 3 REGAL trial. Patients were transplant-ineligible and in second or later remission with AML. HR 0.59 (two-sided p=0.035), median OS 24.0 vs 14.7 months on best available treatment, at the pre-specified 80 deaths. Side effects were mostly grade 1/2 injection-site reactions.

  • Why it matters: Maintenance for transplant-ineligible AML patients in second remission has almost nothing approved, so an OS win here is a real label. The statistics are thin, though: 80 deaths, a two-sided p=0.035 and secondary endpoints still being analysed leave the FDA room to probe control-arm choice and subgroup balance before an accelerated filing. STAT’s Adam Feuerstein, who predicted failure in September, wrote that he was wrong. Sellas launched a $150M offering through J.P. Morgan and TD Cowen the same day, off a $7.47 Monday close, so dilution is the near-term overhang. BLA timing is 1H27 after an FDA meeting. A WT1 vaccine win also gives off-the-shelf AML maintenance a reason for fresh BD interest.

  • Source: STAT

EVERYTHING ELSE THAT BROKE

  • Merck scrapped nemtabrutinib (MK-1026), the oral non-covalent BTK inhibitor from its ArQule buyout, across the whole Phase 3 BELLWAVE program. An independent DMC found its benefits may not outweigh the risks in BELLWAVE-011 in CLL/SLL. — Merck release

  • Kyntra Bio (formerly FibroGen) cut a mid-stage antibody-drug conjugate program from its pipeline. — Fierce Biotech

  • AriBio’s oral PDE5 inhibitor mirodenafil met its monotherapy goal in a global Phase 3 Alzheimer’s trial, with otherwise mixed results; Fosun Pharma holds an option to in-license it. — Fierce Biotech

  • GSK won accelerated FDA approval for Nelkarmi (neladalkib) in ALK-positive NSCLC after prior ALK TKIs, ten days ahead of its 27 Nov goal date. ORR was 49% after alectinib alone and 32% after two or more TKIs plus chemo (ALKOVE-1). It is the second approval from GSK’s $10.6B Nuvalent buyout. — GSK release

  • The FDA’s complete response letter for Summit/Akeso’s ivonescimab faulted the filing’s reliance on China-heavy data, not just the HARMONi survival miss. — Fierce Pharma

  • Beren won FDA approval for Lembaz (adrabetadex), the first medicine shown to improve survival in infantile-onset Niemann-Pick disease type C. — Endpoints

  • Novartis’ Cosentyx won FDA approval for an 11th indication as Novartis works to cushion its 2029 patent cliff. — Fierce Pharma

  • Biogen’s tau ASO diranersen widened its slowing of decline at two years in the Phase 2 CELIA study in early Alzheimer’s, with the 60 mg twice-yearly dose showing the largest effect (CTAD). — Endpoints

  • Inhibrx posted updated ozekibart data in relapsed/refractory Ewing sarcoma: 62.7% ORR and 86.3% DCR. — PR

DEAL FLOW

Track the Deals Shaping Biotech

Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.

M&A / BD&L

  • Viatris completed its $36.50-per-share cash acquisition of Pacira BioSciences (Exparel, Zilretto) after a tender for ~66.5% of shares (announced 8 Oct). — Viatris release (8-K)

VC / PRIVATE FINANCINGS

  • Isomorphic Labs: $5B Series C, co-led by Greenoaks and Sequoia Capital, joined by Alphabet and Andreessen Horowitz. AI drug design, preclinical. — BioSpace

  • Marrow Therapeutics: emerged from stealth with $173M, including a $120M Series B, from 11 investors including founder Scion Life Sciences, OrbiMed and venBio. MAR-101 is a transferrin antibody-siRNA conjugate for sickle cell disease and beta thalassemia, preclinical. — Fierce Biotech

  • Onward Therapeutics: NT$900M (~US$28M) Series B for its clinical-stage oncology pipeline; syndicate not disclosed. — PR

IPO / FOLLOW-ON

  • Sellas (SLS): launched a $150M common stock offering (+$22.5M option) after the REGAL readout. J.P. Morgan and TD Cowen are running it; SLS closed $7.47 on 16 Nov. Unpriced at scan. — Preliminary prospectus (SEC)

ACADEMIC CORNER

  • No relevant academic updates since yesterday’s edition.

Know someone who'd like this?

Forward it along. It takes ten seconds and means a lot to us.

Isomorphic can raise $5B without naming a drug. The FDA can’t name a commissioner.

— The BioBucks Team